Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
Global Broluzumab Biosimilars market was valued at USD 312 million in 2025 and is projected to reach USD 785 million by 2034, exhibiting a CAGR of 10.7% during the forecast period. This significant growth is primarily driven by the increasing prevalence of age-related macular degeneration (AMD) and the rising adoption of biosimilars as cost-effective alternatives to reference biologics.
Brolucizumab is a humanized single-chain antibody fragment designed to treat neovascular (wet) AMD by inhibiting vascular endothelial growth factor A (VEGF-A). This targeted therapy helps control abnormal blood vessel growth and leakage in the retina. The biosimilar versions of brolucizumab offer similar efficacy and safety profiles as the reference product while typically being available at 15-30% lower costs, making them increasingly attractive to healthcare providers and payers.
The market expansion is further supported by key factors including the growing geriatric population susceptible to eye disorders, increasing healthcare expenditure in emerging economies, and recent patent expirations of biologic drugs. Major players like Novartis, Roche, and Samsung Bioepis are actively developing broluzumab biosimilars, with several products currently in late-stage clinical trials. However, stringent regulatory requirements and manufacturing complexities remain challenges for market participants. The Asia-Pacific region is expected to witness the fastest growth due to improving healthcare infrastructure and increasing patient awareness.
Increasing Adoption in Cancer Treatment
The global Broluzumab biosimilars market is witnessing significant growth due to its increasing adoption in treating various cancers, particularly metastatic colorectal cancer. Broluzumab, as a biosimilar to bevacizumab, offers a cost-effective alternative to branded biologics, with 30-50% lower pricing while maintaining comparable efficacy.
Expanding Biosimilar Pipeline
Pharmaceutical companies are heavily investing in the development of Broluzumab biosimilars, with over 15 candidates currently in various stages of clinical trials. This pipeline expansion is accelerating market growth and increasing treatment accessibility worldwide.
The biosimilar market is projected to grow at 23.5% CAGR through 2028, driven by Bozulizumab biosimilars adoption
Patent expirations of reference biologics and favorable regulatory pathways in key markets are further propelling market expansion for Broluzumab biosimilars.
MARKET CHALLENGES
Manufacturing Complexity
Biosimilar production presents significant technical challenges due to the complex molecular structure of Broluzumab. Maintaining consistent quality and biological activity across manufacturing batches requires substantial investment in infrastructure and skilled personnel.
Other Challenges
Physician Resistance
Despite proven efficacy, many oncologists remain hesitant to prescribe Broluzumab biosimilars due to perceived differences from reference products, slowing initial adoption rates.
Regulatory Hurdles
Stringent regulatory requirements for biosimilar approval and interchangeability designations create barriers to market entry, particularly in developed markets with strict compliance standards.
Price Erosion Concerns
Intense competition among Broluzumab biosimilar manufacturers is leading to significant price erosion, with average selling prices declining by approximately 15% annually. This downward pricing pressure is reducing profit margins for market players.
Reimbursement Limitations
Many healthcare systems have implemented restrictive reimbursement policies for biosimilars, with some requiring mandatory switching from reference products or implementing complex prior authorization processes that limit patient access.
Emerging Markets Expansion
Developing nations with growing healthcare expenditure present significant opportunities for Broluzumab biosimilars, as these markets show 40% higher adoption rates for cost-effective biosimilars compared to reference biologics.
New Therapeutic Indications
Ongoing clinical trials exploring Broluzumab biosimilars for additional cancer types beyond their current indications are expected to expand the addressable patient population by approximately 25% within the next five years.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Beovu dominates as the most clinically validated broluzumab biosimilar, benefiting from extensive physician familiarity and strong efficacy in treating wet AMD. The 'Others' category shows promising pipeline products, particularly from emerging biosimilar developers in Asia, though these require additional clinical validation to gain widespread acceptance. |
| By Application |
|
ARMD represents the primary application area where broluzumab biosimilars show greatest clinical utility and market penetration. The VEGF inhibition mechanism proves particularly effective for retinal conditions. Kaposi Sarcoma applications demonstrate niche potential but require specialized oncology protocols. Glioblastoma treatment shows experimental promise but remains in early research phases. |
| By End User |
|
Hospitals constitute the primary adoption channel due to the specialized administration requirements for intravitreal injections and need for sterile environments. Specialty eye clinics demonstrate growing market share as ophthalmology services decentralize. Research institutions show increasing engagement with broluzumab biosimilars for both clinical trials and off-label therapeutic investigations. |
| By Therapeutic Approach |
|
Monotherapy remains the standard of care demonstrating excellent efficacy in wet AMD treatment protocols. Combination therapy shows emerging potential when paired with other VEGF inhibitors for resistant cases. Adjuvant use post-laser therapy presents specialized applications requiring careful dosing protocols to avoid adverse events. |
| By Commercialization Stage |
|
Established Biosimilars currently drive market expansion through competitive pricing while maintaining comparable efficacy. Patented brands maintain premium positioning but face increasing biosimilar substitution pressure. Emerging biosimilars from Asian manufacturers demonstrate cost advantages but require additional clinical data to penetrate Western markets fully. |
Novartis Dominates Brolucizumab Biosimilars Market with Beovu
Novartis maintains market leadership in the brolucizumab biosimilars segment through its branded product Beovu, capturing the majority revenue share in 2025. The competitive landscape features established pharmaceutical giants and specialized biosimilar developers racing to capitalize on the expiring patents for VEGF-A inhibitors. Roche/Genentech and Bayer leverage their ophthalmology expertise to strengthen market positions through strategic partnerships and clinical development pipelines.
Emerging Asian manufacturers like Biocon and Dr. Reddy's are aggressively developing cost-effective brolucizumab biosimilars targeting price-sensitive markets. Specialized biotech firms such as Samsung Bioepis and MAbxience focus on high-quality biosimilar development while contract manufacturers like Sartorius support production scale-up. The market sees increasing competition from Chinese innovators including Innovent and Hengrui Pharmaceuticals investing heavily in biosimilar R&D.
List of Key Brolucizumab Biosimilars Companies ProfiledNovartis AG
Pfizer Inc.
Sartorius AG
Eli Lilly and Company
Samsung Bioepis
Biocon Limited
Dr. Reddy's Laboratories
Aurobindo Pharma
MAbxience
Hetero Drugs
Innovent Biologics
The global Broluzumab Biosimilars market was valued at $520 million in 2025 and is projected to reach $890 million by 2034, growing at a CAGR of 6.2% during the forecast period. This growth is driven by increasing prevalence of neovascular age-related macular degeneration (AMD) and cost-effective alternatives to branded biologics. Brolucizumab biosimilars offer comparable efficacy in inhibiting VEGF-A while reducing treatment costs by 30-50% compared to originator drugs.
Other TrendsRegional Market Expansion
North America currently dominates with 42% market share, but Asia-Pacific is projected to grow at 8.1% CAGR through 2034 due to improving healthcare infrastructure and rising geriatric populations. Europe maintains stable growth with biosimilar-friendly regulatory policies, while emerging markets in Latin America and Middle East show increasing adoption rates.
Manufacturing Capacity InvestmentsKey manufacturers are expanding production facilities to meet growing demand, with contract development organizations playing a larger role. Regulatory approvals for interchangeable biosimilars are expected to increase competition, potentially reducing prices further. Pipeline analysis shows 9 biosimilar candidates in Phase 3 trials across major markets.
Therapeutic Application Growth
While ARMD remains the primary indication (78% of current use), research is expanding into Kaposi sarcoma (12%) and glioblastoma (10%) applications. Clinical trials are investigating extended dosing intervals, which could improve patient compliance and reduce healthcare system burdens.
Pricing and Reimbursement DynamicsMarket access remains a challenge in developing regions due to reimbursement limitations. Value-based pricing models are emerging in developed markets, with payers demanding real-world evidence of efficacy. Patent expirations of originator drugs between 2026-2028 will significantly impact market dynamics and adoption rates.
Regional Analysis: Broluzumab Biosimilars MarketEurope
Europe represents the second largest market for Broluzumab biosimilars, driven by centralized EMA approvals and proactive policies promoting biosimilar use. The region's stringent pricing controls have accelerated biosimilar adoption, with several countries implementing automatic substitution policies. However, market fragmentation across EU member states creates varying adoption rates, with Northern European countries leading in biosimilar penetration compared to Southern counterparts.
Asia-Pacific
The Asia-Pacific region shows the fastest growth potential for Broluzumab biosimilars, led by Japan and South Korea's established biosimilar frameworks. Emerging markets like China and India are investing heavily in domestic biosimilar manufacturing capabilities. Price sensitivity and increasing healthcare access programs are driving demand, though regulatory harmonization remains a challenge across diverse national markets.
South America
South America's Broluzumab biosimilar market is constrained by economic volatility but shows pockets of opportunity in Brazil and Argentina. Regulatory authorities are adapting approval pathways modeled after EMA guidelines. Local production initiatives are emerging, though most biosimilars currently originate from international manufacturers facing patent challenges in the region.
Middle East & Africa
The MEA region presents limited but growing opportunities for Broluzumab biosimilars, with Gulf Cooperation Council countries leading adoption through tender-based procurement systems. Market access remains challenging in lower-income African nations due to affordability constraints, though parallel import channels and charitable programs are expanding treatment access.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252034. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type (Beovu, Vsiqq, Others)
By application (ARMD, Kaposi Sarcoma, Glioblastoma)
By distribution channel
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Biologic drug development trends
Biosimilar manufacturing advancements
Impact of VEGF-A inhibitors
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Regulatory trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Broluzumab Biosimilars market was valued at USD 312 million in 2025 and is projected to reach USD 785 million by 2034.
-> Key players include Novartis, Roche, Genentech, Pfizer, and Samsung Bioepis, among others.
-> Key growth drivers include increasing prevalence of AMD, cost-effectiveness of biosimilars, and patent expirations.
-> Asia-Pacific is the fastest-growing region due to improving healthcare infrastructure.
-> Emerging trends include development of new biologic formulations and expansion of biosimilar manufacturing capabilities.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates